Cardiovascular disease and COVID-19: a consensus paper from the ESC working group on coronary pathophysiology & microcirculation, ESC working group on …

E Cenko, L Badimon, R Bugiardini… - Cardiovascular …, 2021 - academic.oup.com
The cardiovascular system is significantly affected in coronavirus disease-19 (COVID-19).
Microvascular injury, endothelial dysfunction, and thrombosis resulting from viral infection or …

Federated learning for healthcare domain-pipeline, applications and challenges

M Joshi, A Pal, M Sankarasubbu - ACM Transactions on Computing for …, 2022 - dl.acm.org
Federated learning is the process of develo** machine learning models over datasets
distributed across data centers such as hospitals, clinical research labs, and mobile devices …

Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients

T Deuse, X Hu, A Gravina, D Wang, G Tediashvili… - Nature …, 2019 - nature.com
Autologous induced pluripotent stem cells (iPSCs) constitute an unlimited cell source for
patient-specific cell-based organ repair strategies. However, their generation and …

An acute immune response underlies the benefit of cardiac stem cell therapy

RJ Vagnozzi, M Maillet, MA Sargent, H Khalil… - Nature, 2020 - nature.com
Clinical trials using adult stem cells to regenerate damaged heart tissue continue to this
day,, despite ongoing questions of efficacy and a lack of mechanistic understanding of the …

Cardiac fibrosis: Myofibroblast-mediated pathological regulation and drug delivery strategies

M Liu, BL de Juan Abad, K Cheng - Advanced drug delivery reviews, 2021 - Elsevier
Cardiac fibrosis remains an unresolved problem in heart diseases. After initial injury, cardiac
fibroblasts (CFs) are activated and subsequently differentiate into myofibroblasts (myoFbs) …

[HTML][HTML] Longevity leap: mind the healthspan gap

A Garmany, S Yamada, A Terzic - NPJ Regenerative Medicine, 2021 - nature.com
Life expectancy has increased by three decades since the mid-twentieth century. Parallel
healthspan expansion has however not followed, largely impeded by the pandemic of …

A Phase II study of autologous mesenchymal stromal cells and c‐kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN …

R Bolli, RD Mitrani, JM Hare, CJ Pepine… - European journal of …, 2021 - Wiley Online Library
Aims CONCERT‐HF is an NHLBI‐sponsored, double‐blind, placebo‐controlled, Phase II
trial designed to determine whether treatment with autologous bone marrow‐derived …

Cell therapy trials for heart regeneration—lessons learned and future directions

P Menasché - Nature Reviews Cardiology, 2018 - nature.com
The effects of cell therapy on heart regeneration in patients with chronic cardiomyopathy
have been assessed in several clinical trials. These trials can be categorized as those using …

Stem cells in the treatment of disease

HM Blau, GQ Daley - New England Journal of Medicine, 2019 - Mass Medical Soc
Stem-Cell Research and Clinical Application Stem cells have been the focus of hope, hype,
and a great deal of research. But what exactly is a stem cell, and what are its uses? This …

Clinical studies of cell therapy in cardiovascular medicine: recent developments and future directions

MN Banerjee, R Bolli, JM Hare - Circulation research, 2018 - Am Heart Assoc
Given the rising prevalence of cardiovascular disease worldwide and the limited therapeutic
options for severe heart failure, novel technologies that harness the regenerative capacity of …